Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

by | Nov 20, 2026 | Health

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Researchers have reported positive results from a clinical trial of daraxonrasib, an oral medication designed to treat pancreatic cancer. The drug demonstrated efficacy across multiple measures in a trial involving 61 patients with advanced pancreatic cancer that had spread to other organs.

During the trial, tumor growth stopped in 90% of patients. Over 60% experienced tumor shrinkage or complete disappearance, while approximately 8% had tumors that became undetectable on CT scans. In one in 12 patients, cancer became undetectable altogether. Patients were followed for an average of 18 months, with some showing no cancer recurrence during this period. One year after starting treatment, 76.6% of patients remained alive, compared to the typical 40-45% survival rate among patients receiving chemotherapy alone.

Pancreatic cancer remains one of the most difficult cancers to treat, with a median survival of three months for half of those diagnosed and only about 3% surviving five years when the disease has spread to other organs. It carries the lowest survival rate among common cancers in the UK. Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, calling the results “the closest to cure” he had observed.

Daraxonrasib functions as a KRAS inhibitor, targeting specific mutations present in most pancreatic cancers that drive tumor growth. Researchers believe the treatment could potentially be effective for other cancers carrying similar mutations. Michelle Mitchell, chief executive of Cancer Research UK, noted that while more research is needed, the results represent a significant advance for pancreatic cancer patients. Additional trials are required before the treatment can be assessed for use on the NHS, and survival rates for pancreatic cancer remain substantially low overall.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI